Dovato

DTG/3TC dolutegravir/lamivudine

Recommended initial regimen for most people except those with viral load greater than 500,000 copies/mL, hepatitis B virus (HBV) co-infection, or before results of genotypic resistance or HBV testing
Single-Tablet Regimen

Standard Dose

One tablet once daily, without regard to food for treatment-naïve people who have no known resistance to components of the regimen: dolutegravir and lamivudine. Tablet contains 50 mg of the INSTI dolutegravir plus 300 mg of the NRTI lamivudine.

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Dovato is not recommended for people who have severe liver impairment. According to the drug label, Dovato is not recommended for people with decreased kidney function (creatinine clearance less than 50 mL/min) due to the lamivudine component. This medication combination, however, is often used in reduced renal function below 50 mL/min, because of the relatively minimal risk of lamivudine accumulation and side effects. In addition, alternative doses may be obtained by using the individual components of this medication as needed.
  • See the individual drugs contained in this medication: Tivicay and Epivir.
  • See package insert for more complete information on potential side effects and interactions.

Manufacturer

ViiV Healthcare
viivhealthcare.com; dovato.com
(877) 844-8872

AWP

$3,032.81/month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments